About Solentim
Solentim is a company based in Wimborne Minster (United Kingdom) founded in 2010 was acquired by Advanced Instruments in August 2021. The company has 47 employees. Solentim offers products and services including OsmoTECH XT, OsmoPRO MAX, Artel MVS, and GloCyte. Solentim operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Wimborne Minster, United Kingdom
- Employees 47
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website solentim.com
- Social LinkedIn X
- Acquired by Advanced Instruments (Aug 2021)
- Legal Name Advanced Instruments Ltd.
- Date of Incorporation 15 Jun, 2010
- Jurisdiction WIMBORNE, DORSET, ENGLAND
- Latest Funding Round$895.3K (USD), Grant
Jun 2019
- InvestorsAdvanced Instruments
& 1 more
- Employee Count47
- Acquired byAdvanced Instruments
(Aug 2021)
Products & Services of Solentim
Solentim offers a comprehensive portfolio of products and services, including OsmoTECH XT, OsmoPRO MAX, Artel MVS, and GloCyte.
Single-sample micro-osmometer for bioprocessing measurements
Automated osmometer for clinical sample analysis
Multichannel system for liquid handling accuracy
Automated counter for CSF cell analysis in diagnostics
Funding Insights of Solentim
- Total Rounds 2
- Last Round Grant — $895,303
- Investors Count 1
All 2 funding rounds of Solentim with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2019 | $895,303 | Grant | – | – | |
| Mar 2019 | – | Grant | – | – | – |
2 investors in total: 2 institutional.
Investors in Solentim
Solentim has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Advanced Instruments and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
Manufacturer of Laboratory equipment | 1955 | aicompanies.com | Norwood, United States |
Investor details for Solentim
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Solentim
4 dated milestones of Solentim across 11 years, from founding to its latest funding, stage changes and deals.
- Founded Solentim is founded.
- Funding First funding round.
- Funding Latest funding round, Grant, of $895K.
- Exit Acquired by Advanced Instruments.
Competitors of Solentim
Solentim operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| aviditybiosciences.com | 2012 | San Diego, United States | $142.54M | 253 | Antibody-siRNA complexes are developed for cancer treatment. | |
| univercells.com | 2013 | Charleroi, Belgium | $150.64M | 87 | Biomanufacturing technologies are supplied for biopharma antibody and vaccine production. | |
| sutrobio.com | 2003 | United States | $171.85M | 235 | Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis. | |
| vividion.com | 2016 | Oceanside, United States | $270.5M | 123 | Developing novel drugs based on a proteome-wide ligand and target discovery platform | |
| straumann.com | 1954 | Basel, Switzerland | – | – | Dental implants and regenerative dentistry products are developed. | |
| korrobio.com | 2018 | Cambridge, United States | $4M | 77 | RNA-editing technologies are provided for precision medicine applications. | |
| judges.uk.com | 2002 | London, United Kingdom | – | 622 | Acquisition and development of scientific instrument businesses is conducted. | |
| savarapharma.com | 2008 | Austin, United States | $67.82M | 37 | Therapeutics for rare respiratory diseases are developed by Savara Pharma. | |
| antheia.bio | 2013 | Palo Alto, United States | $152.37M | 50 | Yeast cells are genetically engineered to produce medicinal products. | |
| synthego.com | 2012 | Redwood, United States | $459.75M | – | CRISPR-engineered cell and gene therapies are developed for research applications. |
Detailed competitors of Solentim
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solentim
Complete news archive for Solentim
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Solentim
10 companies that operate in the same segment as Solentim (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Solentim
Solentim was founded in 2010 and raised its 1st funding round 9 years after it was founded.
Solentim is headquartered in Wimborne Minster, United Kingdom. It is registered at Wimborne Minster, Dorset, United Kingdom.
Solentim has 47 employees.
Solentim was founded in 2010 and is based in Wimborne Minster, United Kingdom. Operations focus on the biotechnology sector, where cell lines are developed for biotherapeutics, including monoclonal antibodies derived from single cells. These are applied in treatments for conditions such as cancer, autoimmune diseases, and cardiovascular disorders. Services support discovery and manufacturing processes in the biopharmaceutical industry.
Solentim's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Solentim offers OsmoTECH XT, OsmoPRO MAX, Artel MVS, and GloCyte.
Solentim has 2 investors. Key investors include Advanced Instruments, and European Union.
Solentim operates through Advanced Instruments Ltd..
Yes. Solentim was acquired by Advanced Instruments in August 2021.